Capitolis Liquid Global Markets Reduces Bristol Myers Squibb Stake

Hedge fund cuts holdings in pharmaceutical company by over 78% in Q3

Mar. 16, 2026 at 8:37am

Got story updates? Submit your updates here. ›

Capitolis Liquid Global Markets LLC reduced its position in Bristol Myers Squibb Company (NYSE:BMY) by 78.1% during the third quarter, according to a recent SEC filing. The hedge fund now owns 206,000 shares of the biopharmaceutical company's stock, valued at $9.29 million.

Why it matters

This filing provides insight into the investment strategies and portfolio changes of Capitolis Liquid Global Markets, a notable institutional investor. The significant reduction in Bristol Myers Squibb holdings may signal a shift in the fund's outlook on the pharmaceutical company's prospects.

The details

In its 13F filing, Capitolis Liquid Global Markets reported selling 733,200 shares of Bristol Myers Squibb during the third quarter. The fund now holds 206,000 shares, down from 939,200 shares held in the previous quarter. Bristol Myers Squibb is a major biopharmaceutical company focused on oncology, hematology, immunology, and specialty drugs.

  • Capitolis Liquid Global Markets filed its 13F report for the third quarter of 2026.

The players

Capitolis Liquid Global Markets LLC

A hedge fund that manages investments in global financial markets.

Bristol Myers Squibb Company

A major biopharmaceutical company focused on oncology, hematology, immunology, and specialty drugs.

Got photos? Submit your photos here. ›

The takeaway

The significant reduction in Capitolis Liquid Global Markets' Bristol Myers Squibb holdings may signal a shift in the fund's outlook on the pharmaceutical company's prospects, providing insight into the investment strategies of this notable institutional investor.